8-K: Aprea Therapeutics Reports Q1 2026 Results, $30M Private Placement

Aprea Therapeutics announced first quarter 2026 financial results, highlighting two partial responses in its APR-1051 trial and a $30 million oversubscribed private placement to fund ongoing development.

Summary

• Aprea Therapeutics reported its financial results for the first quarter ended March 31, 2026.
• The company announced an oversubscribed $30 million private placement, which closed on March 31, 2026, with proceeds intended for general corporate purposes and R&D.
• Key clinical updates include two partial responses observed in the ongoing Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051.
• One partial response in a uterine carcinosarcoma patient with a PPP2R1A mutation has been confirmed and remains ongoing.
• The company reported $46.5 million in cash and cash equivalents as of March 31, 2026, with an anticipated cash runway into Q1 2028.
• Operating loss for the quarter was $3.4 million, an improvement from $4.1 million in Q1 2025.
• Research and Development expenses decreased to $1.6 million from $2.5 million in Q1 2025, primarily due to the pause in the ABOYA-119 trial.
• Additional clinical data from the ACESOT-1051 trial will be presented at the ASCO 2026 Annual Meeting on May 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by the successful capital raise, encouraging early clinical data for APR-1051, and an extended cash runway, despite the inherent losses of a clinical-stage company.

Positives

• Oversubscribed $30 million private placement closed on March 31, 2026, strengthening the balance sheet.
• Two partial responses observed in the ACESOT-1051 trial evaluating APR-1051, with one confirmed and ongoing.
• Cash and cash equivalents increased to $46.5 million as of March 31, 2026, providing runway into Q1 2028.
• Operating loss decreased to $3.4 million in Q1 2026 from $4.1 million in Q1 2025.
• APR-1051 has demonstrated encouraging tolerability with common adverse events being Grade 1 or 2 nausea and fatigue, and no class-limiting toxicities observed.
• Enrollment in the ACESOT-1051 trial is expanding to include more patients with uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer.
• Eugene (Gene) Kennedy, MD, a seasoned executive, was appointed Chief Medical Advisor in February 2026.

Negatives

• The company reported a net loss of $3.3 million for the quarter ended March 31, 2026.
• Weighted-average common shares outstanding increased significantly to 14.7 million in Q1 2026 from 6.0 million in Q1 2025, impacting loss per share.
• The ABOYA-119 clinical trial has been strategically paused, with an orderly wind-down of certain site activities.
• While two partial responses were observed, one was unconfirmed in a second patient.

Risks

• Risks related to the success, timing, and cost of ongoing and anticipated clinical trials for current product candidates.
• The pace of enrollment and completion of trials, including the ability to fully fund disclosed clinical trials.
• Futility analyses, presentations at conferences, and receipt of interim or preliminary results, which are not necessarily indicative of final results.
• The company's understanding of product candidates' mechanisms of action and interpretation of preclinical and early clinical results.
• The ability to predict clinical outcomes based on preclinical and early clinical results.
• The potential for actual results and developments to differ materially from forward-looking statements due to known or unknown risks and uncertainties.

Future Outlook

The company anticipates its cash and cash equivalents as of March 31, 2026, will be sufficient to meet operating expenses and capital expenditure requirements into the first quarter of 2028. Dose escalation for ACESOT-1051 is anticipated in the second quarter of 2027. Additional clinical updates from ACESOT-1051 are expected during Q2 2026. The company is exploring combination approaches for ATRN-119 with radiation therapy and potentially with immuno-oncology therapies and antibody-drug conjugates.

Management Comments

• We are very encouraged by the progress made across both our clinical and corporate priorities during the first quarter of 2026, including two partial responses observed in the ACESOT-1051 trial evaluating APR-1051.
• These efficacy results, coupled with the encouraging tolerability, support our precision medicine strategy and reinforce the potential of targeted therapies for patients who have limited treatment options.
• The recent $30 million private placement significantly strengthens our balance sheet and enables us to meaningfully expand patient enrollment, generating the clinical data needed to inform the future clinical path for APR-1051.
• We are grateful for the trust and support of both new and existing investors, whose participation reflects confidence in our development strategy and the potential of our programs.

Industry Context

StockSavvy.ai notes that Aprea Therapeutics is operating in the highly competitive and rapidly evolving precision medicine oncology space. The company's focus on WEE1 and ATR inhibitors aligns with industry trends towards targeted therapies that exploit specific cancer vulnerabilities. The observed partial responses, while early, are encouraging in a field where many competitors have faced challenges with therapeutic windows and toxicity.

Comparison to Industry Standards

• Competitor WEE1 inhibitors like Adavosertib (AstraZeneca) and Azenosertib (Zentalis) have faced limitations such as hematologic and GI toxicity, narrow therapeutic windows, and dose reductions/interruptions, suggesting APR-1051's potentially differentiated profile.
• Debio 0123 (Debiopharm) showed QT prolongation liability and limited single-agent activity, indicating potential advantages for APR-1051 if its safety and efficacy profile holds.
• The company's strategy to expand enrollment in ACESOT-1051 for specific patient populations (uterine serous carcinoma, cyclin E-overexpressing platinum-resistant ovarian cancer) reflects a common industry approach to de-risk and advance promising candidates.
• The strategic pause and exploration of combination approaches for ATRN-119 is a typical industry strategy to maximize the potential of drug candidates, especially in areas with high unmet need.

Management Changes

Stakeholder Impact

• Shareholders benefit from the successful $30 million capital raise, which extends the company's runway and supports continued development of its pipeline assets.
• Patients with biomarker-defined cancers may benefit from the ongoing development of APR-1051 and ATRN-119, potentially leading to new treatment options.
• Investors gain confidence from the extended cash runway into Q1 2028 and the positive early clinical signals, potentially supporting future investment.

Next Steps

• Present additional clinical data from ACESOT-1051 at the ASCO 2026 Annual Meeting on May 30, 2026.
• Expand enrollment in ACESOT-1051 to include at least 50 patients with uterine serous carcinoma and patients with cyclin E-overexpressing, platinum-resistant ovarian cancer.
• Complete dose escalation for ACESOT-1051 in the second quarter of 2027.
• Explore combination approaches for ATRN-119 with radiation in HPV+ head and neck cancer.
• Explore investigator-led studies evaluating ATRN-119 with immuno-oncology therapies and antibody-drug conjugates.
• Achieve near-term inflection points and catalysts for the company's programs.

Key Dates

Recommendation

The company has demonstrated progress with a successful capital raise and encouraging early clinical data for APR-1051, extending its cash runway. However, the drug is still in early-stage development, and significant risks remain regarding clinical trial success and regulatory approval. A 'hold' recommendation reflects the balance of positive developments against inherent clinical trial risks and the need for further data.

Keywords

Aprea Therapeutics, APR-1051, WEE1 inhibitor, ACESOT-1051, oncology, clinical trial, biomarker, private placement